source
- Merck and Moderna report personalized mRNA vaccine delays melanoma recurrence in late-stage trialMerck and Moderna announced that a personalized mRNA cancer vaccine, when combined with standard therapy, slowed the return of melanoma and reduced its spread in a late-stage clinical study. The tr…
- Moderna and Merck report success for personalized mRNA vaccine in late-stage melanoma trialModerna and Merck announced that their personalized mRNA cancer vaccine succeeded in a late-stage melanoma study. The vaccine, called intismeran, was evaluated in a randomized Phase 3 trial, the fi…